BRIUMVI momentum is carrying TGTX
- BRIUMVI is the whole story today, with $195 million of U.S. net product revenue in Q1 2026.
- Management raised 2026 U.S. revenue guidance to $885 million to $900 million after record new patient starts.
- New patents extend BRIUMVI composition of matter protection to 2042, giving the franchise a longer runway.
- The main risk is simple: one drug faces a much larger rival in Roche and Genentech.
- The new $750 million credit facility adds cash and buyback power, but also raises debt risk.
A great launch, priced for execution
TGTX is a focused biotech with one major product, BRIUMVI. The drug treats relapsing forms of multiple sclerosis, often called RMS. Q1 2026 was strong: U.S. BRIUMVI net product revenue was $195 million, above the company's own $185 million to $190 million guide.
Management then lifted full-year 2026 U.S. revenue guidance to $885 million to $900 million. That is a big step up from the prior $825 million to $850 million range. The reason matters: the company cited record new patient enrollments and better patient persistence, which means patients are staying on therapy longer than expected.
The bull case is that BRIUMVI has become a real force in the anti-CD20 market for MS. Its one-hour infusion is easy to explain to doctors and patients. New patents that run to 2042 also help protect the long-term profit pool if sales keep scaling.
The bear case is concentration. This is still mostly a one-product company, and it competes with Roche and Genentech, a much larger rival. The Finn view also leaves room for valuation risk: after repeated beat-and-raise quarters, the stock may need nearly perfect execution to work from here.
One MS drug funds the company
TG Therapeutics makes money by selling BRIUMVI in the United States. The drug is distributed mainly through specialty pharmacies and given in infusion centers. Its key pitch is simple: it is an anti-CD20 MS therapy with a one-hour infusion time.
The company runs as a single business segment. Growth comes from adding new patients, keeping existing patients on drug, and winning share from other MS therapies. Management said demand is coming from both community private practices and large academic centers.
Cash from BRIUMVI is being used to expand the commercial effort, fund studies that could improve the label, and support new programs. The company also increased its share repurchase authorization to $300 million after arranging a new five-year, $750 million senior secured credit facility with Blue Owl Capital.
That capital plan cuts both ways. Buybacks show confidence, and the facility brought in $500 million of net new non-dilutive capital after repayment of the old facility. But more debt makes the story less forgiving if BRIUMVI growth slows.
BRIUMVI and ways to extend it
BRIUMVI IV for relapsing MS
This is the approved product and the core business. It generated $195 million of U.S. net product revenue in Q1 2026.
ENHANCE single-day starting dose
This pivotal study tests whether the first two IV starting doses can be combined into one 600 mg dose on day one. Top-line data was expected in the coming weeks as of the Q1 2026 call.
Subcutaneous BRIUMVI
This program would let patients receive BRIUMVI under the skin instead of by IV infusion. The pivotal Phase 3 trial is fully enrolled, with data expected around year-end 2026 or early 2027 and a possible 2028 launch if approved.
Myasthenia gravis study
TG is exploring BRIUMVI in myasthenia gravis, a disease where the immune system weakens muscles. Phase 1 is complete, and a registration-directed Phase 2 study was expected to start in Q2 2026.
Treatment-resistant schizophrenia study
This is an early exploratory effort outside the core MS market. It could broaden the company over time, but it is not central to near-term revenue.
Azer-cel
Azer-cel is an off-the-shelf CD19 CAR T-cell therapy being studied in progressive forms of MS. A Phase 1 dose-escalation study is ongoing, with updates expected later in 2026.
Mostly U.S. BRIUMVI sales
TG Therapeutics reports one operating segment. For investor readability, the mix below uses full-year 2025 revenue color from management: $594 million of U.S. BRIUMVI net sales out of about $616 million of total global revenue, with the rest grouped as other revenue.
What could break the thesis
BRIUMVI slowdown
High impact · Medium oddsThe company depends heavily on one drug. If new starts slow, if patients stop therapy sooner than expected, or if payers tighten access, the raised 2026 guide could come under pressure. Because expectations are now high, even a small miss could matter.
Roche and Genentech pressure
High impact · High oddsTGTX competes in the anti-CD20 MS market against a much larger company with deeper sales reach. BRIUMVI has a clear convenience pitch, but rivals can respond with contracting, doctor outreach, or better delivery options. Share gains are not guaranteed.
Subcutaneous data disappoints
Medium impact · Medium oddsA subcutaneous version could help BRIUMVI compete with patients who prefer at-home or easier dosing. If bioavailability data or pivotal data is weak, that expansion path becomes less valuable. The IV franchise would remain important, but the long-term growth story would narrow.
Debt limits flexibility
Medium impact · Medium oddsThe new $750 million senior secured credit facility gives TG more capital and supports buybacks. It also increases debt. If revenue growth stalls, interest costs and repayment needs could limit research spending or deal activity.
Manufacturing or tariff shock
Medium impact · Low oddsBRIUMVI is currently manufactured in South Korea. Management does not expect a material hit from currently proposed tariffs because cost of goods is low. Still, a supply issue or tariff change could hurt margins or product availability.
In one breath
What does TG Therapeutics sell?
TG Therapeutics sells BRIUMVI, also called ublituximab. It is an anti-CD20 monoclonal antibody used to treat relapsing forms of multiple sclerosis.
Why did TGTX raise its 2026 guidance?
The company said Q1 2026 sales beat its own plan, with $195 million of U.S. BRIUMVI net product revenue. Management pointed to record new patient enrollments and stronger patient persistence.
What are the biggest upcoming catalysts for TGTX?
The near-term catalysts are ENHANCE data for a simplified single 600 mg starting dose and Phase 1 bioavailability data for subcutaneous BRIUMVI. Pivotal subcutaneous BRIUMVI data is expected around year-end 2026 or early 2027.
Is TG Therapeutics profitable?
The internal view treats the company as solidly profitable after the BRIUMVI launch scaled. The key question is whether profit growth can keep pace with debt, buybacks, and pipeline spending.